David Li

David Li, CEO, draws on successful company building expertise and multi disciplinary experience spanning across the life sciences and technology. He previously served as Chief Business Officer at Everest Detection, an early detection liquid biopsy startup founded by Brian Slingerland, CEO and founder of Stemcentrx. Previously, David was the first business hire (6th employee) and led commercial operations at Benchling, a life sciences software platform company which has achieved a $6 billion valuation and has attracted over $500mm in funding from funds such as Altimeter Capital, Tiger Global, Lone Pine Capital, Benchmark, Sequoia, Accel, Lux and numerous others. At Benchling, David led teams of 30+ in sales, marketing, business operations to secure the first several hundred of the company’s biopharma clients. David began his career at Goldman Sachs’ Healthcare investment banking group and KKR’s private equity group where he advised and invested in transactions worth $10 billion+ in enterprise value. He graduated summa cum laude with a B.S. in Economics and B.A. in Molecular Biology from the Roy Vagelos Life Sciences and Management program at the University of Pennsylvania.